Kinostics is Developing a Non-invasive Diagnostic Test For the Detection Of Acute Kidney Injury (aki) At Sub-clinical Stages. The Exosome-aki Test. The Method is Based On Novel And Specific Identification Method Of Biomarkers Present In Urine Microvesicles (called Exosomes) That Allow Early Detection Of Aki. The Company Follows 3 Years Of Research With Promising Results In Cell Lines Animal Models And Humans. Preliminary Clinical Evidence Showed That the Proposed Method Allows the Identification Of Specific Aki Biomarkers Coming From the Kidney In Exosome Fraction Of Urine Therefore Providing Specific Simple And Early Detection Of Kidney Injury Markers That Greatly Surpasses Current Methods Of Aki Detection. Kinostics Approach Will Allow the Diagnosis Of Aki Within a Few Hours Of Kidney Injury With a High Level Of Specificity And Sensibility Thus Enabling Physicians To Make Vital Clinical Decisions To Avoid Damage Progresses To a Potentially Fatal Renal Shutdown. In Addition To Helping Patients Cost-benefit Analyses Show That Kinostics Testing Will Contribute To Reducing Hospital Costs In the Management Of Kidney Injury And Its Consequences. Kinostics Has One Pct Patent Presented In 2011 Covering the Method For Monitoring And Diagnosing Early Stage Aki. The Company Intends To Aggressively Build Its Intellectual Property Portfolio To Fully Protect Its Technology And Future Products. The Company is Currently Working In the Optimization Of the Proprietary Biomarker Selection Method And the Diagnostic Algorithm. A Kit Prototype is Expected By Q2 2014 In Order To Commence Clinical Trials At the Icu Of Clinica Davila In Santiago Chile.